|
|
IsoRay, Inc. is engaged in the development of permanent seed brachytherapy in the treatment of cancers. IsoRay, Inc. has obtained clearance from the United States Food and Drug Administration (FDA) for treatment for all solid tumor applications using Cesium-131 (Cs-131). Such applications include prostate
cancer; ocular melanoma; head, neck and lung tumors; and breast, liver, brain and pancreatic cancer. The seed may be used in surface, interstital and intracavity applications for tumors with known radio sensitivity. On June 1, 2009, the Company expanded its application of Cs-131 with the treatment of a head and neck tumor that could not be accessed by other treatment modalities. IsoRay International LLC (International) is a wholly owned subsidiary of the Company. During fiscal year ended June 30, 2009, the Company divested its ownership in the Russian LLC.
.
( Total: 3 Current Stock Recommendations )
|
|
|
|
|
|
|
|
|
|
* As of 5/24/2013 12:00 AM
|
|
|
|
|